Leadership Team
Kiyotaka Fujii
President, Global Healthcare,
Konica Minolta & Chairman,
Ambry Genetics and Invicro
Kiyotaka Fujii
President, Global Healthcare, Konica Minolta & Chairman, Ambry Genetics
Kiyotaka Fujii leads Konica Minolta’s global healthcare business, which focuses on the advancement of Precision Medicine and Medical Diagnostics. Fujii is also Chairman of Ambry Genetics and Invicro, a biomarker imaging CRO based in Boston.
Fujii’s extensive business career ranges from medical services, information technology, and consumer products to investment banking. Fujii has held several Japan CEO positions with top global companies since 1997, including SAP, Louis Vuitton, Cadence Design Systems and Quintiles Transnational. From 2012 to 2015, he served at Olympus as the first independent board member to re-build its governance and businesses.
From 1986 to 1993, Fujii held the role as the first Japanese M&A investment banker in New York with Credit Suisse First Boston and Goldman Sachs. Fujii began his career with McKinsey as the first hire from a Japanese University.
As the author of "Global Mind," a top-selling Japanese business book, Fujii is often consulted for his perspective as a global business leader in Japan by the government and news media.
Fujii received an MBA from the Harvard Business School in 1986 and a B.A. in Law from the University of Tokyo in 1981.
Ken Masuo
President of Konica Minolta Precision Medicine Japan
Ken Masuo
President of Konica Minolta Precision Medicine Japan
Ken Masuo joined Konica Minolta in 2018 as a senior advisor in our Bio Healthcare business before becoming President of Konica Minolta Precision Medicine Japan, established in October, 2018. Masuo is a well-seasoned executive with a wide range of experience within global pharma companies. He began his career as a clinical development specialist at Daiichi Pharmaceuticals, one of Japan’s largest pharma companies, eventually becoming a Vice President and member of the Board leading their international strategic businesses. Masuo also led the commercial operations at Glaxo-SmithKline as a Senior Managing Director, and was an Executive Director and Japan Representative of Oncology Business at AstraZeneca, Japan, before joining Konica Minolta.
Masuo received an Executive MBA from Temple University, Tokyo in 2001 and a BA and a MS of Agriculture from Kyoto University.
Ken Bloom, MD
CMO, Advanced Pathology & Genomic Services
Dr. Ken Bloom
CMO, Advanced Pathology & Genomic Services
Dr. Bloom brings more than 30 years of clinical and business experience in pathology, oncology, telemedicine, and bioinformatics. His role will be to help expand, strengthen and commercialize the full-suite of precision medicine capabilities offered within the pathology and genomics markets for Invicro and Ambry Genetics.
Previously, Dr. Bloom was President and Head of Oncology & Immunotherapy for Human Longevity Inc., where his team developed and commercialized an industry leading cancer exome product and commercialized a technique for validating neoantigens predicted from sequencing. Dr. Bloom was also instrumental to the business strategy that evolved Clarient from a start-up to the acquisition by GE Healthcare.
Prior to his industry experience, Dr. Bloom spent 15 years within the academic field holding various appointed positions including Director of Laboratory Operations and Chief Information Officer of the Rush Cancer Institute, Clinical Professor of Pathology at University of Southern California, Keck School of Medicine; and Associate Professor of Pathology at Rush Medical College. Dr. Bloom received his MD from Rush Medical College and his BA from Grinnell College.
Ken Masuo
President of Konica Minolta Precision Medicine Japan
Ken Masuo joined Konica Minolta in 2018 as a senior advisor in our Bio Healthcare business before becoming President of Konica Minolta Precision Medicine Japan, established in October, 2018. Masuo is a well-seasoned executive with a wide range of experience within global pharma companies. He began his career as a clinical development specialist at Daiichi Pharmaceuticals, one of Japan’s largest pharma companies, eventually becoming a Vice President and member of the Board leading their international strategic businesses. Masuo also led the commercial operations at Glaxo-SmithKline as a Senior Managing Director, and was an Executive Director and Japan Representative of Oncology Business at AstraZeneca, Japan, before joining Konica Minolta.
Masuo received an Executive MBA from Temple University, Tokyo in 2001 and a BA and a MS of Agriculture from Kyoto University.
Kiyotaka Fujii
President, Global Healthcare, Konica Minolta & Chairman, Ambry Genetics
Kiyotaka Fujii leads Konica Minolta’s global healthcare business, which focuses on the advancement of Precision Medicine and Medical Diagnostics. Fujii is also Chairman of Ambry Genetics and Invicro, a biomarker imaging CRO based in Boston.
Fujii’s extensive business career ranges from medical services, information technology, and consumer products to investment banking. Fujii has held several Japan CEO positions with top global companies since 1997, including SAP, Louis Vuitton, Cadence Design Systems and Quintiles Transnational. From 2012 to 2015, he served at Olympus as the first independent board member to re-build its governance and businesses.
From 1986 to 1993, Fujii held the role as the first Japanese M&A investment banker in New York with Credit Suisse First Boston and Goldman Sachs. Fujii began his career with McKinsey as the first hire from a Japanese University.
As the author of "Global Mind," a top-selling Japanese business book, Fujii is often consulted for his perspective as a global business leader in Japan by the government and news media.
Fujii received an MBA from the Harvard Business School in 1986 and a B.A. in Law from the University of Tokyo in 1981.
Aaron Elliott, PhD
CEO, Ambry Genetics
Dr. Aaron Elliott
CEO, Ambry Genetics
Dr. Elliott joined Ambry Genetics in 2008 in the research and development department working closely on the development of comprehensive molecular diagnostic tests. An innovator in complex genetic testing, Dr. Elliott has been involved in the conception and implementation of many of the diagnostic industry first to market tests and technologies including the first commercial NGS assay, CLIA/CAP Exome test and hereditary cancer panels among others. Dr. Elliott and the Ambry team were instrumental in mounting a creative defense in the groundbreaking University of Utah Research Foundation, et al., v. Ambry Genetics Corporation case which ended the monopoly of BRCA testing in the United States.
Dr. Elliott has helped guide the company through extreme periods of growth, including the recent acquisition by Konica Minolta. Over the years he has held many leadership positions at Ambry, including Director of Genomic Services, Chief Operating Officer and Chief Scientific Officer.
Dr. Elliott began his career as a Postdoctoral Fellow at the Novartis Institute of Functional Genomics in San Diego, where he conducted research on potential drug targets for chemotherapeutic resistance and tumor formation. As part of this research, Dr. Elliott helped in identifying the first mitochondrial ABC transporter in cancer cells, which are responsible for multi-drug resistance in many solid tumors.
A graduate of Franklin and Marshall College, Dr. Elliott conducted his Ph.D. Genetics training at Thomas Jefferson University and The Johns Hopkins University School of Medicine.
Jack Hoppin, PhD
Co-founder and CEO, Invicro
Dr. Jack Hoppin
Co-founder and CEO, Invicro
Jack Hoppin, Ph.D., is chief executive officer and co-founder of Invicro, a global leading provider of imaging services, software solutions, and advanced data analysis in research and drug development. Dr. Hoppin oversees the overall corporate strategy and direction to ensure sponsors receive the highest standard of service through collaborative R&D, business development, operational excellence and valuable partnerships.
Dr. Hoppin co-founded Invicro with co-founder Dr. Christian Lackas, and founding partners Janna Murgia and Dr. Jacob Hesterman in late 2008. Today, Invicro has grown its team of professionals to 340+ strong, including over 200 research scientists- consisting of more than 60 MDs or Ph.Ds. Currently, Invicro has over 350 pre-clinical and clinical research trials open, and has realized about a 90% CAGR since it first full year of business in 2009. In 2017, Invicro was sold to Konica Minolta to integrate synergistic capabilities under the precision medicine offering, specifically the novel quantitative pathology technology invented by Konica Minolta. The company operates out of four core office and laboratory locations including its headquarters in Boston, as well as New Haven- CT, Doylestown-PA, and London-U.K. Invicro was honored for two consecutive years by Inc. Magazine as one of the fastest growing privately held companies in the U.S. in 2013 and 2014.
Prior to Invicro, from 2006 to 2009, Dr. Hoppin served as vice president of Imaging Systems at Bioscan Inc. in New York, NY. As vice president, Dr. Hoppin oversaw Bioscan’s lion share of the business – bringing the imaging product line to market through product development, research collaborations, and ensuring the technical sales and application support were fully aligned and succinctly executed. From 2005 to 2006, Dr. Hoppin was a project manager for Bioscan based out of Aachen, Germany and Budapest, Hungary, where he managed the development, and launch of the NanoSPET/CT system that went on to win multiple innovation awards and generated over 100 million dollars of revenue.
Prior to his industry experience, Dr. Hoppin was the Alexander von Humboldt post-doctoral fellow at the Research Center Jülich, Center for Electronics in Jülich, Germany from 2003 to 2005.
Dr. Hoppin holds four patents and over 30 peer-reviewed articles. Dr. Hoppin received his Ph.D. in applied mathematics from the University of Arizona, and is active in multiple academic societies serving on the Board of Trustees for the World Molecular Imaging Society, the Industry Board for the Society of Nuclear Medicine and a member of the Harvard Catalyst Biomarker Faculty.
Dr. Aaron Elliott
CEO, Ambry Genetics
Dr. Elliott joined Ambry Genetics in 2008 in the research and development department working closely on the development of comprehensive molecular diagnostic tests. An innovator in complex genetic testing, Dr. Elliott has been involved in the conception and implementation of many of the diagnostic industry first to market tests and technologies including the first commercial NGS assay, CLIA/CAP Exome test and hereditary cancer panels among others. Dr. Elliott and the Ambry team were instrumental in mounting a creative defense in the groundbreaking University of Utah Research Foundation, et al., v. Ambry Genetics Corporation case which ended the monopoly of BRCA testing in the United States.
Dr. Elliott has helped guide the company through extreme periods of growth, including the recent acquisition by Konica Minolta. Over the years he has held many leadership positions at Ambry, including Director of Genomic Services, Chief Operating Officer and Chief Scientific Officer.
Dr. Elliott began his career as a Postdoctoral Fellow at the Novartis Institute of Functional Genomics in San Diego, where he conducted research on potential drug targets for chemotherapeutic resistance and tumor formation. As part of this research, Dr. Elliott helped in identifying the first mitochondrial ABC transporter in cancer cells, which are responsible for multi-drug resistance in many solid tumors.
A graduate of Franklin and Marshall College, Dr. Elliott conducted his Ph.D. Genetics training at Thomas Jefferson University and The Johns Hopkins University School of Medicine.
Scientific Advisory Board Members
John Niederhuber, MD
President and CEO of the Genomics and Bioinformatics Research Institute
John Niederhuber, MD
President and CEO of the Genomics and Bioinformatics Research Institute
Previously, Dr. Niederhuber served as the Director of the National Cancer Institute, National Institutes of Health, and currently serves as the Executive Vice President and CEO of Inova Translational Medicine Institute (ITMI) and is the newly appointed President and CEO of the Genomics and Bioinformatics Research Institute (GBRI), a new research institute jointly funded by the University of Virginia and the Inova Health System. He is also a Professor of Public Health Sciences at the University of Virginia School of Medicine, Adjunct Professor of Oncology and Surgery at Johns Hopkins University School of Medicine, and Deputy Director of the Johns Hopkins Clinical Research Network.
Dr. Niederhuber has dedicated his highly successful career to the study and treatment of cancer. As a child growing up in a small steel mill town in Ohio, he was inspired by the local doctor who often made house calls on his way home, understanding then the value of personalized patient care. Dr. Niederhuber passionately believes that the precise blending of oncology, radiation, imaging and pathology offers the best solutions for complex diseases like cancer, by matching more patients to more effective therapies.
Judy E. Garber, MD, MPH
Chief of the Division of Cancer Genetics and Prevention at Dana-Farber Cancer Institute
Dr. Judy E. Garber
Chief of the Division of Cancer Genetics and Prevention at Dana-Farber Cancer Institute
Dr. Garber is the Susan F. Smith Chair and Chief of the Division of Cancer Genetics and Prevention at Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School. She conducts research in clinical cancer genetics, with a special focus in the genetics of breast cancer. She has played a major role in the development of national guidelines in cancer genetics. Dr. Garber is also a leader in research into the characteristics and treatment of triple negative or basal-like breast cancer, the most common form in women with BRCA1 mutations and an expert in Li-Fraumeni Syndrome. Her translational research focuses on the evaluation of novel agents targeting DNA repair defects in breast cancer, including PARP inhibitors for treatment and prevention of breast cancer and other BRCA-associated cancers.
Dr. Garber is a past president of the American Association for Cancer Research (AACR). She serves on the National Cancer Advisory Board of the National Cancer Institute and was elected into the National Academy of Medicine in 2013. She also serves as the Co-Scientific Director of the Breast Cancer Research Foundation and past chair of the Breast Cancer Research Foundation Scientific Advisory Board. She is an ASCO Statesman and a Fellow of the AACR Academy.
David Rimm, MD, PhD
Professor, Departments of Pathology and Medicine (Oncology) at the Yale University School of Medicine
John Niederhuber, MD
President and CEO of the Genomics and Bioinformatics Research Institute
Previously, Dr. Niederhuber served as the Director of the National Cancer Institute, National Institutes of Health, and currently serves as the Executive Vice President and CEO of Inova Translational Medicine Institute (ITMI) and is the newly appointed President and CEO of the Genomics and Bioinformatics Research Institute (GBRI), a new research institute jointly funded by the University of Virginia and the Inova Health System. He is also a Professor of Public Health Sciences at the University of Virginia School of Medicine, Adjunct Professor of Oncology and Surgery at Johns Hopkins University School of Medicine, and Deputy Director of the Johns Hopkins Clinical Research Network.
Dr. Niederhuber has dedicated his highly successful career to the study and treatment of cancer. As a child growing up in a small steel mill town in Ohio, he was inspired by the local doctor who often made house calls on his way home, understanding then the value of personalized patient care. Dr. Niederhuber passionately believes that the precise blending of oncology, radiation, imaging and pathology offers the best solutions for complex diseases like cancer, by matching more patients to more effective therapies.
Dr. Judy E. Garber
Chief of the Division of Cancer Genetics and Prevention at Dana-Farber Cancer Institute
Dr. Garber is the Susan F. Smith Chair and Chief of the Division of Cancer Genetics and Prevention at Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School. She conducts research in clinical cancer genetics, with a special focus in the genetics of breast cancer. She has played a major role in the development of national guidelines in cancer genetics. Dr. Garber is also a leader in research into the characteristics and treatment of triple negative or basal-like breast cancer, the most common form in women with BRCA1 mutations and an expert in Li-Fraumeni Syndrome. Her translational research focuses on the evaluation of novel agents targeting DNA repair defects in breast cancer, including PARP inhibitors for treatment and prevention of breast cancer and other BRCA-associated cancers.
Dr. Garber is a past president of the American Association for Cancer Research (AACR). She serves on the National Cancer Advisory Board of the National Cancer Institute and was elected into the National Academy of Medicine in 2013. She also serves as the Co-Scientific Director of the Breast Cancer Research Foundation and past chair of the Breast Cancer Research Foundation Scientific Advisory Board. She is an ASCO Statesman and a Fellow of the AACR Academy.
David Rimm, MD, PhD
Professor, Departments of Pathology and Medicine (Oncology) at the Yale University School of Medicine
Dr. David Rimm is a Professor in the Departments of Pathology and Medicine (Oncology) at the Yale University School of Medicine. He is the Director of Yale Pathology Tissue Services. He completed an MD-PhD at Johns Hopkins University Medical School followed by a Pathology Residency at Yale and a Cytopathology Fellowship at the Medical College of Virginia. He is boarded in Anatomic and Cytopatholgy. His research lab group focuses on quantitative pathology using the AQUA® technology invented in his lab, and other quantitative methods, with projects related to predicting response to both targeted and immune- therapy in cancer and standardization of those assays for CLIA labs. His lab is involved in testing new high-plex methods including imaging mass cytometry (Fluidigm) and digital spatial profiling (NanoString) He also has supported projects related to rapid, low cost diagnostic tests and direct tissue imaging. The work is supported by grants from the NIH, BCRF, and sponsored research agreements from biopharma. He also serves on the CAP Immunohistochemistry committee and multiple scientific advisory boards for biotech and pharma. He is an author of over 350 peer-reviewed papers and 8 patents.
Geoffrey Ginsburg, MD, PhD
Founding Director, Center for Applied Genomics & Precision Medicine at the Duke University Medical Center
Geoffrey S Ginsburg, MD, PhD
Founding Director, Center for Applied Genomics & Precision Medicine at the Duke University Medical Center
Dr. Ginsburg is the founding director for the Center for Applied Genomics & Precision Medicine at the Duke University Medical Center and for MEDx, a partnership between the Schools of Medicine and Engineering to spark and translate innovation. His research addresses the challenges for translating genomic information into medical practice and the integration of precision medicine into healthcare. In 2017 he received Duke’s Translational Research Mentorship Award.
He is a member of the Advisory Council to the Director of NIH and is co-chair of the National Academies Roundtable on Genomic and Precision Health and is founder and president of the Global Genomic Medicine Collaborative, a not for profit organization aimed creating international partnerships to advance the implementation of precision medicine. He has recently served as a member of the Board of External Experts for the NHLBI, the advisory council for the National Center for Accelerating Translational Science, the chair of the review for Genome Canada’s Large Scale Applied Research Competition in Genomics and Precision Medicine, and the World Economic Forum’s Global Agenda Council on the Future of the Health Sector. He was previously Vice President of Molecular Medicine at Millennium Pharmaceuticals, Inc and a faculty member at Harvard Medical School.
Giovanni Parmigiani, PhD
Associate Director for Population Sciences of the Multi-Institutional Dana-Farber/Harvard Cancer Center
Giovanni Parmigiani
Associate Director for Population Sciences of the Multi-Institutional Dana-Farber/Harvard Cancer Center
Giovanni Parmigiani's research investigates statistical principles and tools, often with a focus on understanding cancer data. For example, he is currently interested in addressing the challenges of cross-study replication of predictions, by constructing predictors that learn replicability from being trained on multiple studies at once. He also has a long term interest in helping families who are particularly susceptible to inherited cancer understand their risk and make informed decisions. He uses Bayesian modeling and machine learning concepts to predict who is at risk of carrying genetic variants, and to integrate literature-based and other information about the effects of mutations. Visit the BayesMendel page to find out more about this line of investigation.
Throughout his research activities, his broad goals are to find innovative ways to use data science and data technologies to fuel cancer prevention and early detection and, methodologically, to increase the rigor end efficiency with which we leverage the vast and complex information generated in today’s cancer research. He strives to foster the use of data sciences as a common thread to facilitate interactions between fields and academic cultures, and has a passion for mentoring and training young(er) scientists in interdisciplinary settings.
Since joining Harvard in 2009 he has taken on several leadership roles: he is the Associate Director for Population Sciences of the multi-institutional Dana-Farber / Harvard Cancer Center (DF/HCC), and is the director of the postdoctoral training grant in Quantitative Sciences for Cancer Research at the Harvard T.H. Chan School of Public Health, where he is a Professor. He has been the Chairman of the Department of Biostatistics & Computational Biology at Dana-Farber Cancer Institute from 2009 to 2018, and the Leader of the DF/HCC Biostatistics and Computational Biology Program (now Cancer Data Sciences Program) from 2009 to 2015.
Howard I. Scher, MD
Co-Chair, Center for Mechanism Based Therapy and Head of the Biomarker Development Initiative at Memorial Sloan Kettering Cancer Center
Geoffrey S Ginsburg, MD, PhD
Founding Director, Center for Applied Genomics & Precision Medicine at the Duke University Medical Center
Dr. Ginsburg is the founding director for the Center for Applied Genomics & Precision Medicine at the Duke University Medical Center and for MEDx, a partnership between the Schools of Medicine and Engineering to spark and translate innovation. His research addresses the challenges for translating genomic information into medical practice and the integration of precision medicine into healthcare. In 2017 he received Duke’s Translational Research Mentorship Award.
He is a member of the Advisory Council to the Director of NIH and is co-chair of the National Academies Roundtable on Genomic and Precision Health and is founder and president of the Global Genomic Medicine Collaborative, a not for profit organization aimed creating international partnerships to advance the implementation of precision medicine. He has recently served as a member of the Board of External Experts for the NHLBI, the advisory council for the National Center for Accelerating Translational Science, the chair of the review for Genome Canada’s Large Scale Applied Research Competition in Genomics and Precision Medicine, and the World Economic Forum’s Global Agenda Council on the Future of the Health Sector. He was previously Vice President of Molecular Medicine at Millennium Pharmaceuticals, Inc and a faculty member at Harvard Medical School.
Giovanni Parmigiani
Associate Director for Population Sciences of the Multi-Institutional Dana-Farber/Harvard Cancer Center
Giovanni Parmigiani's research investigates statistical principles and tools, often with a focus on understanding cancer data. For example, he is currently interested in addressing the challenges of cross-study replication of predictions, by constructing predictors that learn replicability from being trained on multiple studies at once. He also has a long term interest in helping families who are particularly susceptible to inherited cancer understand their risk and make informed decisions. He uses Bayesian modeling and machine learning concepts to predict who is at risk of carrying genetic variants, and to integrate literature-based and other information about the effects of mutations. Visit the BayesMendel page to find out more about this line of investigation.
Throughout his research activities, his broad goals are to find innovative ways to use data science and data technologies to fuel cancer prevention and early detection and, methodologically, to increase the rigor end efficiency with which we leverage the vast and complex information generated in today’s cancer research. He strives to foster the use of data sciences as a common thread to facilitate interactions between fields and academic cultures, and has a passion for mentoring and training young(er) scientists in interdisciplinary settings.
Since joining Harvard in 2009 he has taken on several leadership roles: he is the Associate Director for Population Sciences of the multi-institutional Dana-Farber / Harvard Cancer Center (DF/HCC), and is the director of the postdoctoral training grant in Quantitative Sciences for Cancer Research at the Harvard T.H. Chan School of Public Health, where he is a Professor. He has been the Chairman of the Department of Biostatistics & Computational Biology at Dana-Farber Cancer Institute from 2009 to 2018, and the Leader of the DF/HCC Biostatistics and Computational Biology Program (now Cancer Data Sciences Program) from 2009 to 2015.
Howard I. Scher
Co-Chair, Center for Mechanism Based Therapy and Head of the Biomarker Development Initiative
Co-Chair, Center for Mechanism Based Therapy; Head of the Biomarker Development Initiative; Member and Attending Physician, Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center (MSKCC), Professor of Medicine at the Weill Cornell Medical College, and the D. Wayne Calloway Chair in Urologic Oncology. Dr. Scher’s research is focused on the codevelopment of targeted therapies and biomarkers such as circulating tumor cells (CTCs) which can be used to guide treatment selection for the individual patient and improve the way drugs are evaluated in the clinic, accelerating regulatory approvals. Accordingly, he has led international efforts to standardize the design and analysis of phase II prostate cancer trials (PCWG2, PCWG3) and helped elucidate key molecular and genetic features of prostate cancer, translating these insights into the clinic by leading early phase and phase III registration trials of abiraterone acetate and enzalutamide which are now FDA approved. Dr. Scher serves as the principal investigator of the NIH Specialized Program of Research Excellence (SPORE) in Prostate Cancer at MSKCC and the Department of Defense-sponsored Prostate Cancer Clinical Trials Consortium (PCCTC), and has received the 2015 AACR Team Science Award for his multidisciplinary work developing AR inhibitors. Most recently Dr. Scher was elected to the Association of American Physicians and named a Fellow of the American Society of Clinical Oncology (ASCO).
